文献速递淋巴瘤

早期完全缓解作为结外边缘区淋巴瘤全身治疗中经过验证的替代标志物

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy.
PubMed 文献 · Blood · 2024-01-01

本研究基于国际结外淋巴瘤研究组19项3期试验的401例患者,评估24个月内完全缓解时间(TTCR24)和24个月时完全缓解(CR24)能否作为8年无进展生存期(8y-PFS)的替代标志物。双药治疗(利妥昔单抗+苯丁酸氮芥)较单药治疗(利妥昔单抗或苯丁酸氮芥)的完全缓解累积发生率更高(风险比1.75,P<.001)。TTCR24解释了95%的治疗效果(95%CI 0.27-1.87),CR24介导了90%的治疗效果(95%CI 0.51-2.22),两者可作为临床试验中有效的早期指标。

要点

  • 在401例患者中,264例(66%)在24个月内达到完全缓解,其中222例(84%)在24个月时维持完全缓解。
  • 双药治疗组较单药治疗组的完全缓解累积发生率更高(风险比1.75,P<.001)。
  • TTCR24解释了95%的治疗对8y-PFS的效应,CR24介导了90%的治疗效应。

核心结论

  • TTCR24和CR24可作为临床试验中信息丰富且有效的早期指标,反映治疗对PFS的效应。

研究设计与样本

  • 基于国际结外淋巴瘤研究组19项3期试验的401例患者,采用两种近期发表的单试验方法评估TTCR24和CR24是否为8年PFS的良好替代标志物。

主要发现

  • 401例患者中264例(66%)在最初24个月内达到完全缓解,其中222例(84%)在24个月时维持完全缓解。
  • 双药治疗组完全缓解累积发生率显著高于单药治疗组(风险比1.75,P<.001)。
  • 双药治疗组与更高的CR24率、更短的TTCR24和更长的8y-PFS相关。
  • TTCR24解释的8y-PFS治疗效应比例为95%(95%CI 0.27-1.87)。
  • CR24介导了90%的治疗对PFS的效应(95%CI 0.51-2.22),其自然间接效应在整个随访期间显著。

临床怎么用

  • 作者认为TTCR24和CR24可在临床试验中作为信息丰富且有效的早期指标,反映治疗对PFS的效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extranodal marginal zone lymphoma (EMZL) has a very indolent course, and the validation of surrogate markers could accelerate novel therapies. Although prognostic markers do exist, no surrogate markers have been validated in EMZL. We hypothesized that time to complete response within 24 months (TTCR24) and complete response (CR) at 24 months (CR24) could be valid surrogate markers of progression-free survival (PFS). The International Extranodal Lymphoma Study Group 19 phase 3 trial showed the advantage of double therapy (rituximab + chlorambucil) over single therapy (rituximab or chlorambucil) on PFS. We used 2 recently published single-trial approaches to assess whether TTCR24 and CR24 were good surrogate markers of 8-year PFS (8y-PFS). Among the 401 patients, 264 (66%) reached a CR in the first 24 months, of which 222 (84%) remained in CR at month 24. The cumulative incidence of CR over time was significantly higher in patients under double therapy (hazard ratio, 1.75; P < .001). The double therapy arm was associated with a higher CR24 rate, a shorter TTCR24, and a longer 8y-PFS. The estimated proportion of treatment effect on 8y-PFS explained by TTCR24 was 95% (95% confidence interval [CI], 0.27-1.87). CR24 was also a strong surrogate marker because it mediated 90% (95% CI, 0.51-2.22) of the treatment effect on PFS and its natural indirect effect was significant throughout the follow-up. We found that TTCR24 predicted 95% and that CR24 mediated 90% of the treatment effect on long-term PFS. Therefore, TTCR24 and CR24 could be used in clinical trials as informative and valid early indicators of treatment effect on PFS. This trial was registered at www.clinicaltrials.gov as #NCT00210353.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bommier C, Zucca E, Chevret S, et al. Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy. Blood. 2024. PMID: 37801707. doi:10.1182/blood.2023020984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。